Wockhardt Ltd 2017 AR2
The report highlights Wockhardt's Golden Jubilee Year, marking five decades of growth and research and development achievements. During the fiscal year 2016-17, the company focused on its New Chemical Entity (NCE) research program, with the US FDA granting an abridged clinical trial for Phase III of its superdrug antibiotic WCK 5222. Despite facing politico-economic challenges such as Brexit and demonetisation in India, the company continued its commitment to corporate social responsibility through the Wockhardt Foundation, impacting nearly 3 million lives annually. Additionally, Wockhardt received GMP compliance confirmations from UK MHRA and HPRA Ireland for several manufacturing facilities.
Company: Wockhardt Ltd
Sector: Health Care
Country: India
Year: 2017
Type: AR2
Pages: 224
Wockhardt Ltd
Annual Report
The report highlights Wockhardt's Golden Jubilee Year, marking five decades of growth and research and development achievements. During the fiscal year 2016-17, the company focused on its New Chemical Entity (NCE) research program, with the US FDA granting an abridged clinical trial for Phase III of its superdrug antibiotic WCK 5222. Despite facing politico-economic challenges such as Brexit and demonetisation in India, the company continued its commitment to corporate social responsibility through the Wockhardt Foundation, impacting nearly 3 million lives annually. Additionally, Wockhardt received GMP compliance confirmations from UK MHRA and HPRA Ireland for several manufacturing facilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees